A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: A stratification tool for prospective clinical trials

被引:162
作者
Leibovich, BC
Cheville, JC
Lohse, CM
Zincke, H
Frank, I
Kwon, ED
Merchan, JR
Blute, ML
机构
[1] Mayo Clin Rochester, Dept Urol, Rochester, MN 55905 USA
[2] Mayo Clin Rochester, Dept Lab Med & Pathol, Rochester, MN 55905 USA
[3] Mayo Clin Rochester, Dept Hlth Sci Res, Rochester, MN 55905 USA
[4] Mayo Clin Rochester, Dept Med Oncol, Rochester, MN 55905 USA
[5] Mayo Clin Rochester, Mayo Med Sch, Rochester, MN 55905 USA
关键词
kidney neoplasms; carcinoma; renal cell; neoplasm metastasis; survival;
D O I
10.1097/01.ju.0000177487.64651.3a
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We developed a clinically useful scoring algorithm to predict cancer specific survival for patients with clear cell metastatic renal cell carcinoma (RCC). Materials and Methods: We studied 727 patients treated with radical nephrectomy for clear cell RCC from 1970 to 2000 who had distant metastases at nephrectomy (285) or in whom metastases subsequently developed (442). A scoring algorithm to predict cancer specific survival was developed using the regression coefficients from a Cox proportional hazards model. Results: There were 606 deaths from clear cell RCC at a median of 1.0 years (range 0 to 14) following metastatic RCC. Constitutional symptoms at nephrectomy (+2), metastases to the bone (+2) or liver (+4), metastases in multiple simultaneous sites (+2), metastases at nephrectomy (+1) or within 2 years of nephrectomy (+3), complete resection of all metastatic sites (-5), tumor thrombus level I to IV (+3), and the primary pathological features of nuclear grade 4 (+3) and histological tumor necrosis (+2) were significantly associated with death from RCC. All patients started with a score of 0 and points were added or subtracted as indicated in parentheses. Cancer specific survival rates at 1 year were 85.1%, 72.1%, 58.8%, 39.0%, and 25.1%, respectively, for patients with scores of -5 to -1, scores of 0 to 2, scores of 3 to 6, scores of 7 or 8, and scores of 9 or more. Conclusions: This scoring algorithm can be used to predict cancer specific survival for patients with metastatic clear cell RCC.
引用
收藏
页码:1759 / 1763
页数:5
相关论文
共 24 条
  • [1] Prognostic impact of histologic Subtyping of adult renal epithelial neoplasms - An experience of 405 cases
    Amin, MB
    Amin, MB
    Tamboli, P
    Javidan, J
    Stricker, H
    Venturina, MD
    Deshpande, A
    Menon, M
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (03) : 281 - 291
  • [2] The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus
    Blute, ML
    Leibovich, BC
    Lohse, CM
    Cheville, JC
    Zincke, H
    [J]. BJU INTERNATIONAL, 2004, 94 (01) : 33 - 41
  • [3] Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma
    Cheville, JC
    Lohse, CM
    Zincke, H
    Weaver, AL
    Blute, ML
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (05) : 612 - 624
  • [4] Sarcomatoid renal cell carcinoma - An examination of underlying histologic subtype and an analysis of associations with patient outcome
    Cheville, JC
    Lohse, CM
    Zincke, H
    Weaver, AL
    Leibovich, BC
    Frank, I
    Blute, ML
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2004, 28 (04) : 435 - 441
  • [5] An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score
    Frank, I
    Blute, ML
    Cheville, JC
    Lohse, CM
    Weaver, AL
    Zincke, H
    [J]. JOURNAL OF UROLOGY, 2002, 168 (06) : 2395 - 2400
  • [6] Gelb AB, 1997, CANCER-AM CANCER SOC, V80, P981
  • [7] Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma
    Han, KR
    Pantuck, AJ
    Bui, MHT
    Shvarts, O
    Freitas, DG
    Zisman, A
    Leibovich, BC
    Dorey, FJ
    Gitlitz, BJ
    Figlin, RA
    Belldegrun, AS
    [J]. UROLOGY, 2003, 61 (02) : 314 - 319
  • [8] Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO
  • [9] 2-4
  • [10] Kankuri M, 2001, CANCER-AM CANCER SOC, V92, P761, DOI 10.1002/1097-0142(20010815)92:4<761::AID-CNCR1380>3.0.CO